{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T21:51:50Z","timestamp":1761429110763,"version":"3.41.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jpba.2015.08.004","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T05:18:12Z","timestamp":1438924692000},"page":"443-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["UPLC\u2013MS\/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells"],"prefix":"10.1016","volume":"115","author":[{"given":"Amedeo De","family":"Nicol\u00f2","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan Mohamed","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Boglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Baiett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Allegra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Di","family":"Perri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2015.08.004_bib0005","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2015.08.004_bib0010","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/cid\/cir774","article-title":"Boceprevir and telaprevir in the management of hepatitis C virus-infected patients","volume":"54","author":"Butt","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2015.08.004_bib0015","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.clinthera.2012.08.009","article-title":"Boceprevir: a protease inhibitor for the treatment of hepatitis C","volume":"34","author":"Chang","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jpba.2015.08.004_bib0020","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2015.08.004_bib0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/jvh.12170","article-title":"Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir","volume":"21","author":"Boglione","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.jpba.2015.08.004_bib0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.antiviral.2014.06.005","article-title":"Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner","volume":"109","author":"De Nicol\u00f2","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.jpba.2015.08.004_bib0035","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.26602","article-title":"Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir","volume":"59","author":"Mauss","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2015.08.004_bib0040","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000000189","article-title":"Determination of the HCV protease inhibitor telaprevir in plasma and dried blood spot by liquid chromatography tandem mass spectrometry","author":"Verweij-van Wissen","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2015.08.004_bib0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jpba.2013.02.025","article-title":"A UPLC\u2013MS\/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir","volume":"78\u201379","author":"D\u2019Avolio","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2015.08.004_bib0050","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/bmc.3211","article-title":"Validation of a sensitive LC\/MS\/MS method for the determination of telaprevir and its R-isomer in human plasma","volume":"28","author":"Chen","year":"2014","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2015.08.004_bib0055","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jchromb.2013.06.013","article-title":"Validation of an electrospray ionisation LC\u2013MS\/MS method for quantitative analysis of telaprevir and its R-diastereomer","volume":"932","author":"Penchala","year":"2013","journal-title":"J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2015.08.004_bib0060","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1016\/j.jchromb.2009.10.013","article-title":"Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503,034) and telaprevir (VX 950) in human plasma by LC\u2013MS\/MS","volume":"877","author":"Farnik","year":"2009","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2015.08.004_bib0065","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jchromb.2006.12.038","article-title":"Ultra-performance liquid chromatography\/tandem mass spectrometric determination of diastereomers of SCH 503034 in monkey plasma","volume":"852","author":"Wang","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2015.08.004_bib0070","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jpba.2013.11.027","article-title":"Development and validation of a useful UPLC\u2013MS\/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients","volume":"90","author":"Agnesod","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2015.08.004_bib0075","unstructured":"FDA, Guidance for Industry: Bioanalytical Method Validation, http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm368107.pdf (2013)."},{"key":"10.1016\/j.jpba.2015.08.004_bib0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jpba.2014.05.040","article-title":"UPLC\u2013MS\/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells","volume":"98","author":"De Nicol\u00f2","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2015.08.004_bib0085","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1093\/jac\/dku234","article-title":"Intracellular accumulation of atazanavir\/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms","volume":"69","author":"D\u2019Avolio","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2015.08.004_bib0090","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jpba.2012.03.030","article-title":"Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients","volume":"66","author":"D\u2019Avolio","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2015.08.004_bib0095","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/jac\/dks484","article-title":"Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells","volume":"68","author":"D\u2019Avolio","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2015.08.004_bib0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jpba.2011.10.003","article-title":"HPLC\u2013MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)","volume":"59","author":"D\u2019Avolio","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2015.08.004_bib0105","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jpba.2010.10.011","article-title":"A HPLC\u2013MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation","volume":"54","author":"D\u2019Avolio","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2015.08.004_bib0110","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/FTD.0000000000000013","article-title":"Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia","volume":"36","author":"De Francia","year":"2014","journal-title":"Ther. Drug. Monit."},{"key":"10.1016\/j.jpba.2015.08.004_bib0115","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1128\/AAC.00104-14","article-title":"Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens","volume":"58","author":"De Nicolo","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2015.08.004_bib0120","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1128\/AAC.01236-10","article-title":"Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations","volume":"55","author":"Simiele","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2015.08.004_bib0125","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clinbiochem.2004.11.007","article-title":"Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry","volume":"38","author":"Taylor","year":"2005","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jpba.2015.08.004_bib0130","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/hep.24636","article-title":"Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon\/ribavirin treatment in patients infected with hepatitis C virus genotype 1\/4","volume":"54","author":"D\u2019Avolio","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2015.08.004_bib0135","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/FTD.0b013e31824bf778","article-title":"Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment","volume":"34","author":"D\u2019Avolio","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2015.08.004_bib0140","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/FTD.0b013e318272e55a","article-title":"Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG\/IFN-RBV treatment","volume":"34","author":"D\u2019Avolio","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2015.08.004_bib0145","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1086\/524086","article-title":"Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment","volume":"46","author":"Bonora","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2015.08.004_bib0150","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1097\/01.aids.0000247121.19951.fa","article-title":"Unexpected drug\u2013drug interaction between tipranavir\/ritonavir and enfuvirtide","volume":"20","author":"Gonzalez de Requena","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.jpba.2015.08.004_bib0155","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/jvh.12162","article-title":"Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir\/pegylated interferon\/ribavirin therapy for chronic hepatitis C","volume":"21","author":"Karino","year":"2013","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.jpba.2015.08.004_bib0160","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpba.2014.03.040","article-title":"Therapeutic drug monitoring of intracellular anti-infective agents","volume":"101","author":"D\u2019Avolio","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2015.08.004_bib0165","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00216-009-3263-1","article-title":"Development and validation of a simultaneous extraction procedure for HPLC\u2013MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma","volume":"396","author":"Baietto","year":"2009","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2015.08.004_bib0170","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/FTD.0b013e318189596d","article-title":"An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients","volume":"30","author":"D\u2019Avolio","year":"2008","journal-title":"Ther. Drug. Monit."},{"key":"10.1016\/j.jpba.2015.08.004_bib0175","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jchromb.2006.10.030","article-title":"A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method","volume":"848","author":"D\u2019Avolio","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci."},{"key":"10.1016\/j.jpba.2015.08.004_bib0180","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jchromb.2007.10.003","article-title":"HPLC\u2013MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients","volume":"859","author":"D\u2019Avolio","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708515301023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708515301023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T22:29:01Z","timestamp":1748557741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708515301023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":36,"alternative-id":["S0731708515301023"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2015.08.004","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UPLC\u2013MS\/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2015.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}